lymphoma
potenti
life
threaten
diseas
goal
studi
investig
therapeut
potenti
natur
triterpenoid
ganoder
acid
gaa
control
lymphoma
growth
vitro
vivo
show
gaa
treatment
induc
caspasedepend
apoptot
cell
death
character
dosedepend
increas
activ
caspas
upregul
proapoptot
bim
bax
protein
subsequ
loss
mitochondri
membran
potenti
releas
cytochrom
c
addit
gaa
antigrowth
activ
show
lower
dose
gaa
enhanc
hla
class
iimedi
antigen
present
cell
recognit
lymphoma
vitro
therapeut
relev
gaa
treatment
also
test
vivo
use
syngen
mous
model
metastat
lymphoma
gaatreat
significantli
prolong
surviv
challeng
mice
decreas
tumor
metastasi
liver
outcom
accompani
mark
downregul
phosphoryl
reduct
myeloidderiv
suppressor
cell
mdsc
enhanc
cytotox
cell
host
thu
gaa
select
induc
apoptosi
lymphoma
cell
also
enhanc
cellmedi
immun
respons
attenu
mdsc
elev
ag
present
cell
recognit
demonstr
therapeut
benefit
indic
gaa
candid
futur
drug
design
treatment
lymphoma
current
cancer
therapeut
possess
mani
desir
properti
new
natur
product
capabl
modul
prolifer
immunogen
cancer
cell
becom
keyston
search
new
treatment
strategi
notabl
disadvantag
exist
chemotherapi
lymphoid
malign
resist
small
percentag
tumor
drug
induc
cytotox
result
longterm
ineffect
treatment
ultim
diseas
relaps
ocker
hopfner
souza
et
al
henc
induc
enhanc
immun
respons
resist
tumor
cell
immunemedi
clearanc
longterm
surviv
may
achiev
key
aspect
gener
immun
respons
bcell
lymphoma
includ
hla
class
iimedi
antigen
present
cell
morkowski
et
al
howev
bcell
lymphoma
unabl
optim
process
antigen
deliveri
cell
via
hla
class
ii
molecul
crucial
step
result
escap
cell
immun
drenou
et
al
hossain
et
al
larg
number
aggress
bcell
lymphoma
also
lack
unabl
deliv
ag
cell
via
hla
class
pathway
thu
activ
hla
class
ii
pathway
immun
recognit
may
help
expand
maintain
small
number
tumorspecif
cell
studi
report
ganoder
acida
gaa
natur
extract
medicin
mushroom
ganoderma
lucidum
fig
potenti
play
dualrol
chemoand
immunotherapeut
regimen
human
bcell
lymphoma
ganoderma
use
centuri
far
east
countri
folk
remedi
antitumor
health
promot
effect
hsieh
wu
sliva
due
presum
health
benefit
appar
absenc
sideeffect
also
wide
consum
dietari
supplement
cancer
patient
hsieh
wu
major
constitu
ganoderma
includ
polysaccharid
triterpen
boh
et
al
wubshet
et
al
compon
seem
profound
antiprolif
activ
chen
et
al
kimura
et
al
sadava
et
al
ganoder
acid
ga
one
major
compound
potent
pharmacolog
activ
found
g
lucidum
compound
belong
triterpenoid
wide
believ
ga
possess
numer
properti
includ
antioxid
anticanc
antivir
antiplatelet
aggreg
properti
although
crude
ga
deriv
test
mani
occas
jiang
et
al
liu
et
al
wu
et
al
yao
et
al
purifi
gaa
investig
detail
molecular
formula
gaa
approxim
molecular
mass
dalton
natur
product
may
potenti
play
import
role
immun
regul
inhibit
leukemia
lymphoma
growth
afford
gaa
may
also
provid
window
opportun
coadministr
tradit
anticanc
drug
overcom
cancer
cell
resist
chemotherapi
bcell
lymphoma
aris
lymphoid
organ
due
unpreced
atyp
prolifer
lymphoid
cell
thu
compromis
immun
function
siegel
et
al
diseas
regard
lead
caus
new
cancer
case
unit
state
recent
estim
leukemia
lymphoma
account
new
cancer
case
new
cancerrel
death
us
bcell
lymphoma
also
occur
age
develop
progress
malign
involv
complex
interact
neoplast
bcell
surround
microenviron
highlight
need
new
therapeut
strategi
recent
studi
suggest
myeloidderiv
suppressor
cell
mdsc
repres
subset
antigen
present
cell
accumul
tumor
microenviron
induc
immun
toler
malign
goh
et
al
kennedi
et
al
khale
et
al
mdsc
compris
hematopoiet
progenitor
cell
precursor
macrophag
dendrit
cell
immatur
granulocyt
cell
great
interest
capac
suppress
adapt
immun
respons
mediat
cell
promot
tumor
growth
metastasi
mougiakako
et
al
srivastava
et
al
remain
unclear
whether
gaa
caus
alter
mdsc
lymphoma
neg
influenc
immun
recognit
regulatori
cell
treg
also
play
essenti
role
immunosuppress
network
contribut
tumorimmun
evas
facciaben
et
al
studi
investig
vitro
vivo
efficaci
gaa
treatment
control
growth
bcell
lymphoma
vitro
find
suggest
gaa
induc
apoptosi
human
bcell
lymphoma
equal
concentr
gaa
less
toxic
healthi
primari
bcell
blymphoblastoid
cell
line
also
show
gaa
treatment
enhanc
cell
recognit
lymphoma
cell
vivo
data
show
gaa
treatment
reduc
tumor
load
simultan
kill
lymphoma
cell
enhanc
immun
recognit
via
reduct
mdsc
activ
cytotox
cell
host
human
preb
acut
lymphocyt
leukemia
burkitt
lymphoma
ramo
daudi
nonhodgkin
lymphoma
toledo
db
cell
line
maintain
describ
previous
god
et
al
radwan
et
al
human
epsteinbarr
viru
ebv
transform
blymphoblastoid
cell
line
blcl
frev
priess
cultur
complet
imdm
media
describ
toledo
db
cell
line
purchas
american
type
cultur
collect
atcc
st
loui
mo
ramo
daudi
cell
radwan
et
al
obtain
dr
janic
blum
indiana
univers
transduc
use
retrovir
vector
constitut
express
link
drug
select
marker
hygromycin
histidinol
resist
haqu
et
al
hiraiwa
et
al
kovat
et
al
radwan
et
al
express
surfac
complex
cell
confirm
flow
cytometr
analysi
use
mab
hiraiwa
et
al
radwan
et
al
cell
transduc
use
retrovir
vector
constitut
express
hladm
molecul
haqu
et
al
kovat
et
al
express
hladm
molecul
cell
confirm
western
blot
cell
hybridoma
line
respond
human
serum
albumin
hsa
residu
human
specif
cell
hybridoma
line
maintain
complet
media
haqu
et
al
zhao
et
al
primari
tumor
includ
follicular
bcell
lymphoma
tb
diffus
larg
bcell
lymphoma
tb
chronic
lymphocyt
lymphoma
tb
obtain
holl
cancer
center
musc
pi
approv
protocol
hr
institut
review
board
irb
medic
univers
south
carolina
studi
particip
provid
written
consent
particip
studi
approv
irb
primari
bcell
separ
healthi
volunt
blood
sampl
use
human
naiv
bcell
enrich
kit
stemcel
technolog
inc
vancouv
canada
per
manufactur
instruct
human
hsa
peptid
vklvnevtefaktk
produc
use
fmoc
technolog
appli
biosystem
synthes
describ
haqu
et
al
hossain
et
al
zhao
et
al
primari
antibodi
use
human
caspas
ganoder
acid
gaa
fig
isol
ganoderma
lucidum
mushroom
purchas
apin
chemic
ltd
uk
cat
puriti
gaa
determin
vendor
use
lcm
analysi
gaa
reconstitut
dmso
fisher
scientif
make
stock
solut
use
cell
viabil
assay
vitro
gaa
treatment
final
dmso
concentr
exceed
vv
cell
seed
cellswel
appropri
cultur
medium
flatbottom
plate
gaa
ad
appropri
well
final
concentr
follow
gaa
treatment
cell
viabil
measur
use
celltit
aqueou
one
solut
cell
prolifer
assay
mt
promega
madison
wi
radwan
et
al
data
repres
least
three
separ
experi
express
cell
viabil
control
sd
triplic
well
estim
cell
death
lymphomapati
primari
bcell
nonviabl
cell
treat
control
batch
count
trypan
blue
dye
exclus
percent
cell
death
calcul
dose
gaa
use
estim
ic
valu
analyz
use
nonlinear
regress
analysi
sigmoid
doserespons
equat
graphpad
prism
experi
repeat
least
three
time
data
express
percent
cell
death
sd
triplic
well
lymphoma
cell
treat
differ
concentr
gaa
subject
subsequ
assay
cellular
activ
caspas
briefli
cell
plate
total
volum
plate
treat
gaa
plate
equilibr
min
room
temperatur
caspaseglo
reagent
promega
corpor
madison
wi
ad
well
luminesc
record
min
ad
reagent
use
floustar
optima
micropl
reader
bmg
durham
nc
describ
analyz
caspas
activ
cell
treat
ga
presenc
absenc
pancaspas
inhibitor
zvadfmk
final
concentr
r
system
cell
treat
vehicl
alon
use
control
cell
incub
cell
viabil
measur
use
mt
assay
describ
cell
treat
vehicl
alon
gaa
stain
annexin
vfitc
propidium
iodid
pi
describ
examin
mitochondri
dysfunct
may
contribut
cytochrom
c
releas
cell
treat
vehicl
alon
gaa
stain
tmre
tetramethylrhodamin
ethyl
ester
sigma
analyz
flow
cytometri
accord
manufactur
protocol
triplic
sampl
analyz
facscan
flow
cytomet
use
cellquest
softwar
bd
bioscienc
mountain
view
ca
cell
treat
gaa
vehicl
alon
incub
wash
dulbecco
phosphatebuff
salin
fraction
describ
previous
surjit
et
al
briefli
cell
resuspend
ice
cold
buffer
hepe
ph
edta
egta
mm
dithiothreitol
proteas
inhibitor
cocktail
min
ice
follow
addit
vortex
vigor
second
sampl
first
spun
min
pellet
nuclei
confirm
microscopi
supernat
clarifi
min
use
cytoplasm
fraction
subsequ
western
blot
analysi
detect
cytochrom
c
protein
use
protein
load
control
rel
protein
express
also
assess
use
biorad
scan
densitomet
state
ratio
specif
protein
sampl
radwan
et
al
zhao
et
al
treat
control
cell
gaa
vehicl
alon
stain
antibodi
follow
fluorescein
isothiocyan
fitc
label
secondari
antibodi
antirat
igg
santa
cruz
haqu
et
al
hiraiwa
et
al
zhao
et
al
background
fluoresc
evalu
use
irrelev
isotypematch
mab
zhao
et
al
subtract
nonspecif
background
mean
fluoresc
intens
mfi
use
compar
rel
protein
express
cell
surfac
treat
control
cell
express
mhc
class
class
ii
costimulatori
molecul
cell
surfac
spleen
cell
obtain
gaa
treat
control
mice
also
analyz
briefli
spleen
cell
gaa
treat
group
untreat
group
ii
control
group
iii
incub
fitcconjug
antimous
mhc
class
antimous
class
ii
iaie
antimous
antimous
antibodi
santa
cruz
intracellular
stain
pool
lymph
nodespleen
cell
santa
cruz
also
perform
use
standard
protocol
appropri
conjug
isotypematch
igg
serv
control
stain
flow
cytometr
analysi
perform
three
independ
assay
use
facscan
cellquest
softwar
bd
bioscienc
mountain
view
ca
determin
serum
igg
andor
igm
level
cell
pb
incub
sera
obtain
vehicl
alon
gaa
treat
mice
min
wash
incub
fitcconjug
mous
antiigg
antiigm
antibodi
bethyl
laboratori
montgomeri
tx
usa
min
cell
wash
fix
paraformaldehyd
analyz
flow
cytomet
analyz
produc
cell
spleen
cell
vehicl
gaatreat
mice
pool
treat
ngml
pma
plu
ngml
ionomycin
stain
pelabel
rat
antimous
monoclon
antibodi
bd
pharmingen
clone
cat
wash
cell
fix
permeabil
subsequ
stain
fitclabel
rat
antimous
clone
cat
cell
analyz
flow
cytometri
cell
cellswel
treat
either
vehicl
alon
gaa
cultur
media
plate
examin
chang
cellular
abil
present
exogen
antigen
treatment
hsa
hsa
peptid
ad
appropri
well
last
incub
cell
wash
cocultur
hsa
peptid
specif
cell
hybridoma
product
cultur
supernat
test
elisa
haqu
et
al
radwan
et
al
younger
et
al
test
chang
present
endogen
antigen
cell
express
endogen
treat
gaa
wash
cocultur
human
peptid
specif
cell
hybridoma
anoth
cell
product
quantit
elisa
mention
god
et
al
radwan
et
al
amount
cultur
supernat
correspond
activ
cell
assay
repeat
least
three
time
male
mice
week
old
averag
obtain
jackson
laboratori
tumorbear
mous
model
establish
mice
previous
describ
imai
et
al
knoepp
et
al
mice
hous
specif
pathogen
free
condit
room
temperatur
humid
commonli
avail
chow
tap
water
mous
cell
lymphoma
line
cell
pb
inject
iv
two
group
mice
group
group
ii
micegroup
third
group
group
iii
contain
mice
use
repres
sham
control
group
gaa
treatment
group
receiv
seri
three
ip
dose
gaa
contain
bodi
weight
day
inject
respect
final
concentr
volum
gaa
ip
inject
dmso
per
mous
meanwhil
control
group
untreat
sham
receiv
equival
volum
per
mous
vehicl
solut
tumorbear
anim
sacrif
show
sever
sign
move
disabl
hamper
obtain
food
water
necropsi
done
scarifi
anim
examin
number
liver
tumor
liver
weight
liver
appear
knoepp
et
al
work
mice
approv
medic
univers
south
carolina
anim
protocol
review
board
perform
accord
nation
institut
health
guid
care
use
laboratori
anim
data
experiment
group
subject
statist
analysi
differ
experiment
group
analyz
statist
signific
use
student
ttest
analysi
varianc
anova
appropri
valu
p
consid
signific
screen
gaa
antiprolif
effect
carri
simultan
sever
earli
passag
human
bcell
lymphoma
blymphoblastoid
cell
line
addit
primari
bcell
lymphoma
healthi
bcell
obtain
lymphoma
patient
healthi
donor
gaa
treatment
induc
signific
dosedepend
antiprolif
activ
reduc
viabil
lymphoma
cell
test
calcul
ic
rang
burkitt
lymphoma
fig
nonhodgkin
lymphoma
fig
significantli
lower
viabil
detect
gaatreat
blymphoblastoid
cell
ic
rang
fig
notabl
gaa
caus
nearli
increas
reduct
viabil
lymphoma
cell
line
averag
compar
blymphoblastoid
cell
line
addit
similar
antigrowth
activ
assay
show
gaa
elicit
notabl
decreas
cell
viabil
primari
tumor
compar
normal
healthi
bcell
fig
data
gaa
treatment
show
averag
decreas
cell
viabil
primari
bcell
lymphoma
vs
reduct
cell
growth
healthi
primari
bcell
taken
togeth
data
demonstr
preferenti
antiprolif
activ
gaa
blymphoma
cell
line
primari
tumor
compar
bcell
line
healthi
primari
bcell
studi
mechan
gaamedi
antiprolif
activ
human
lymphoma
focus
known
preb
acut
lymphocyt
leukaemia
line
blymphoblastoid
cell
line
western
blot
analysi
treat
cell
show
presenc
cleav
caspas
protein
suggest
gaa
mediat
apoptot
cell
death
activ
process
caspas
number
catalyt
subunit
fig
gaainiti
cleavag
caspas
follow
dosedepend
fashion
greater
extent
observ
cell
compar
bcell
line
less
sensit
gaa
fig
signific
increas
caspas
catalyt
activ
caspas
also
measur
cell
treatment
gaa
fig
pancaspas
inhibitor
zvadfmk
known
bind
catalyt
site
caspas
almost
complet
revers
antiprolif
activ
observ
cell
fig
determin
magnitud
apoptot
event
gaatreat
cell
stain
annexin
v
bind
extern
phosphatidylserin
earli
stage
apoptosi
flow
cytomert
analysi
treat
fig
lower
left
column
show
two
separ
subpopul
low
forward
scatter
fsc
high
side
scatter
ssc
profil
characterist
apoptot
cell
analysi
gate
cell
show
higher
proport
cell
stain
annexin
v
combin
earli
late
stage
apoptosi
vs
control
cell
fig
right
column
apoptot
cell
doublestain
annexin
v
pi
suggest
entri
pi
apoptot
cell
earli
stage
damag
cell
membran
occur
lower
percentag
cell
apoptosi
detect
bcell
line
equival
event
data
shown
taken
togeth
find
suggest
gaainduc
cell
death
mediat
increas
caspas
express
activ
consequ
led
apoptot
cell
death
bcell
lymphoma
next
examin
molecular
mechan
regul
gaainduc
apoptosi
lymphoma
western
blot
analys
whole
cell
lysat
perform
measur
antiapoptot
protein
survivin
compar
express
proapoptot
bax
cytochrom
c
follow
gaa
treatment
data
show
signific
downregul
survivin
protein
gaatreat
cell
wherea
upregul
bax
protein
detect
versu
cell
fig
analysi
cytoplasm
fraction
also
show
higher
level
kda
cytochrom
c
protein
gaa
treat
cell
fig
previou
studi
suggest
proapoptot
protein
bim
play
import
role
baxmedi
cytochrom
c
releas
induct
apoptosi
akiyama
et
al
merino
et
al
oreilli
et
al
zhao
et
al
thu
examin
whether
gaa
effect
bim
protein
express
bcell
lymphoma
treatment
lymphoma
cell
gaa
show
three
isoform
bim
upregul
fig
suggest
elev
bim
molecul
may
involv
bax
activ
possibl
mitochondri
depolar
determin
whether
gaa
inde
induc
mitochondri
dysfunct
control
gaa
treat
cell
stain
tmre
wash
analyz
flow
cytometri
data
show
decreas
tmre
fluoresc
intens
gaatreat
cell
compar
vehicl
treat
cell
fig
presum
depolar
mitochondri
membran
potenti
preced
cytochrom
c
releas
cytosol
releas
cytochrom
c
may
subsequ
promot
activ
presenc
caspas
could
form
larg
multimer
apoptosom
franklin
robertson
hu
et
al
activ
downstream
caspas
cascad
induc
cell
death
lymphoma
examin
whether
gaa
treatment
abl
improv
antitumor
immun
via
enhanc
hla
class
ii
protein
express
cancer
cell
reinstal
function
antigen
present
cell
western
blot
analysi
treat
cell
show
substanti
upregul
hla
class
ii
pathway
compon
hladr
ii
hladm
cell
supplement
fig
b
flow
cytometr
analysi
confirm
gaa
treatment
slightli
significantli
increas
cell
surfac
molecul
cell
compar
vehicletr
cell
supplement
fig
similar
pattern
cell
surfac
molecul
also
observ
gaa
treat
cell
compar
vehicl
treat
control
supplement
fig
next
essenti
examin
increas
level
class
ii
express
due
gaa
treatment
influenc
lymphoma
antigen
present
reinstal
function
cell
recognit
cancer
thu
effect
gaa
treatment
cellcanc
cell
interact
immun
respons
test
sever
lymphoma
compar
parallel
experi
use
profession
antigen
present
bcell
line
priess
fig
level
immun
recognit
measur
amount
product
supernat
collect
coincub
treat
control
cell
antigen
specif
cell
exogen
fig
endogen
fig
present
antigen
lymphoma
cell
significantli
enhanc
treat
less
gaa
observ
gaa
although
antiprolif
significantli
increas
cell
recognit
cell
treatment
cell
gaa
caus
rel
lower
cell
respons
compar
treatment
gaa
presum
due
greater
antiprolif
effect
seen
lymphoma
compar
normal
bcell
fig
nevertheless
immun
respons
induc
gaa
treatment
may
biolog
signific
sinc
smaller
number
viabl
cell
still
abl
potenti
antigen
present
immun
activ
taken
togeth
data
suggest
gaa
treatment
potenti
reinstal
antitumor
immun
may
repres
valuabl
tool
immun
clearanc
lymphoma
examin
antitumor
role
gaa
vivo
use
well
character
lymphoma
model
model
cell
inject
tail
vein
syngen
mice
metastas
gener
liver
tumor
imai
et
al
knoepp
et
al
mice
bear
tumor
either
left
untreat
given
seri
intraperiton
dose
gaa
mgkg
bodi
weight
day
respect
data
show
mice
administ
gaa
surviv
significantli
longer
mice
treat
vehicl
alon
mean
surviv
day
vs
day
respect
n
p
fig
untreat
vehicl
treat
mice
show
slight
loss
bodi
weight
increas
liver
size
compar
gaa
treat
one
fig
also
detect
significantli
fewer
number
liver
metastas
tumor
nodul
gaatreat
mice
compar
vehicletr
mice
fig
data
suggest
gaa
capabl
prolong
surviv
tumorbear
mice
substanti
inhibit
tumor
growth
liver
metastas
serum
spleenlymph
node
cell
gaatreat
control
anim
also
test
determin
whether
gaa
play
role
subsequ
vivo
immun
stimul
result
show
slight
increas
serum
igg
igm
level
gaatreat
mice
compar
vehicletr
control
fig
howev
differ
statist
signific
flow
cytometr
analysi
pool
spleenlymph
node
cell
show
signific
differ
cell
surfac
express
mhci
mhcii
molecul
among
gaa
treat
control
group
howev
slight
upregul
cell
surfac
express
mfi
vs
respect
observ
fig
data
shown
mdsc
believ
induc
tumorassoci
factor
play
import
role
suppress
host
immun
respons
regulatori
cell
treg
also
play
key
role
mainten
immunolog
selftoler
suppress
antitumor
immun
respons
see
signific
differ
treg
popul
fig
detect
profound
reduct
mdsc
popul
gaatreat
mice
fig
analysi
popul
reveal
gaa
treatment
significantli
inhibit
mdsc
mice
fig
histolog
analysi
liver
sampl
control
test
group
confirm
mark
reduct
metastat
lesion
gaa
treat
mice
fig
data
suggest
gaa
treatment
may
activ
cellular
immun
respons
control
tumor
growth
increas
ag
present
upregul
molecul
reduct
mdsc
host
one
key
transcript
factor
involv
activ
mdsc
signal
transduc
activ
transcript
kujawski
et
al
thu
test
liver
pool
spleen
cell
pool
vehicl
gaatreat
mice
statu
western
blot
shown
fig
gaa
treatment
suppress
level
spleen
cell
obtain
gaa
treat
mice
examin
gaa
treatment
influenc
cytotox
cell
host
perform
surfac
intracellular
flow
cytometr
analysi
determin
produc
cell
spleen
cell
data
obtain
assay
show
gaa
treatment
markedli
increas
number
produc
cell
compar
vehicl
control
fig
suggest
gaa
potenti
induc
antitumor
immun
reduc
burden
metastat
lymphoma
current
use
chemotherapi
regimen
lymphoid
malign
although
effect
mani
case
drawback
exhibit
high
level
treatmentassoci
toxic
effect
even
pronounc
elderli
patient
campbel
et
al
yamaguchi
et
al
zhou
et
al
anoth
drawback
tradit
chemotherapi
resist
small
percentag
tumor
treatment
result
longterm
therapi
eventu
diseas
relaps
borchmann
et
al
hann
keseru
thu
search
new
natur
antitumor
compound
signific
antigrowth
activ
abil
restor
immunogen
target
cancer
cell
increasingli
becom
focu
develop
novel
treatment
strategi
lymphoma
abil
gener
immun
respons
chemotherapyresist
tumor
cell
could
ultim
restor
immun
lead
tumor
clearanc
present
studi
show
clearli
g
lucidumderiv
triterpenoid
gaa
exhibit
profound
antitumor
properti
inhibit
cell
prolifer
alter
intracellular
signal
pathway
induct
apoptosi
treatment
gaa
induc
remark
dosedepend
antiprolif
activ
lymphoma
cell
line
well
primari
tumor
significantli
lower
antigrowth
activ
healthi
cell
addit
antiprolif
effect
tumor
cell
data
highlight
first
time
gaa
capabl
enhanc
hla
class
iimedi
antigen
present
cell
recognit
bcell
lymphoma
gaa
treatment
upregul
intracellular
surfac
express
hla
class
ii
molecul
bcell
lymphoma
correl
enhanc
antigen
present
cell
stimul
although
gaa
greater
antigrowth
activ
lymphoma
cell
compar
antigen
present
blymphoblastoid
cell
rel
fewer
viabl
lymphoma
cell
still
capabl
stimul
strong
cell
respons
vitro
apoptosi
mechan
program
cell
death
thought
key
mechan
maintain
tissu
homeostasi
especi
hematopoiet
system
fecteau
kipp
kerr
et
al
kerr
et
al
thu
resist
apoptot
cell
death
contribut
develop
hematolog
malign
data
suggest
gaa
induc
caspasedepend
apoptosi
major
pathway
induc
cell
death
mechan
cell
death
support
upregul
cleavag
caspas
caspas
express
correl
increas
catalyt
activ
cellular
caspas
furthermor
cellular
caspas
inhibit
zvadfmk
antiprolif
activ
drastic
reduc
suggest
key
role
effector
caspas
execut
gaainduc
cell
death
result
impli
apoptot
event
regul
least
part
upregul
proapoptot
protein
bim
multibh
domain
proapoptot
protein
bax
downregul
antiapoptot
protein
analysi
cytoplasm
fraction
gaatreat
cell
show
signific
upregul
accompani
greater
releas
mitochondri
cytochrom
c
lymphoma
cell
compar
healthi
bcell
counterpart
find
suggest
possibl
scenario
induc
intrins
apoptot
pathway
initi
migrat
bax
surfac
mitochondria
subsequ
inhibit
antiapoptot
effect
suggest
gaa
induc
reduct
ratio
caus
dysfunct
mitochondri
membran
potenti
indic
lower
tmre
stain
treat
cell
caus
cytochrom
c
releas
releas
cytochrom
c
crucial
promot
activ
facilit
format
larg
multimer
apoptosom
activ
downstream
effector
caspas
lead
induct
apoptosi
lymphoma
cell
order
investig
potenti
therapeut
relev
vitro
data
antitumor
effect
gaa
examin
vivo
use
syngen
lymphoma
mous
model
found
administr
gaa
significantli
suppress
metastasi
lymphoma
cell
liver
correl
improv
surviv
treg
often
associ
poor
clinic
outcom
facciaben
et
al
studi
nt
find
signific
chang
treg
cell
vehicl
vs
gaa
treat
mice
contrast
found
gaa
treatment
attenu
tumor
growth
metastasi
mark
inhibit
mdsc
popul
host
could
regul
via
pathway
kujawski
et
al
well
recogn
mdsc
promot
immun
escap
tumor
cell
via
inhibit
cell
respons
result
tumor
growth
metastasi
deng
et
al
sawant
et
al
wesolowski
et
al
interest
reduct
mdsc
correl
increas
number
produc
cell
might
play
critic
role
reduc
tumor
burden
gaa
treat
anim
constitut
activ
mdsc
also
upregul
antiapoptot
proprolif
proangiogen
factor
thu
inhibit
phosphoryl
gaa
treatment
could
accomplish
therapeut
outcom
model
recent
studi
also
support
involv
mdsc
prognost
factor
variou
clinic
set
possibl
therapeut
approach
toward
elimin
immunosuppress
activ
enhanc
antitumor
immun
respons
deng
et
al
srivastava
et
al
wesolowski
et
al
also
import
note
mdsc
well
studi
variou
tumorbear
host
significantli
expand
suppress
antitumor
immun
respons
compar
naiv
counterpart
poschk
et
al
srivastava
et
al
conclus
studi
suggest
gaa
possess
sever
antitumor
properti
make
attract
candid
develop
novel
therapeut
first
exhibit
signific
select
antigrowth
activ
toward
cancer
cell
may
provid
target
mechan
wherebi
tumor
cell
clear
limit
side
effect
secondli
lower
dose
gaa
induc
upregul
hla
class
ii
may
prove
enhanc
ag
present
cell
recognit
target
cancer
cell
third
gaa
attenu
mdsc
popul
possibl
inhibit
phosphoryl
fourth
gaa
treatment
potenti
antitumor
immun
respons
activ
produc
cell
final
amelioratori
effect
gaa
shown
vivo
evidenc
e
primari
bcell
lymphoma
patient
healthi
individu
treat
gaa
follow
cell
viabil
assay
describ
method
section
control
cell
treat
vehicl
alon
util
calcul
percent
antiprolif
activ
induc
gaa
indic
primari
bcell
obtain
lymphoma
patient
includ
follicular
bcell
lymphoma
tb
diffus
larg
bcell
lymphoma
tb
chronic
lymphocyt
leukemia
tb
cell
treat
vehicl
alon
gaa
viabl
cell
count
use
trypan
blue
dye
exclus
percent
cell
viabil
compar
control
calcul
describ
method
data
shown
result
least
three
separ
experi
perform
triplic
well
error
bar
repres
mean
sd
signific
differ
indic
p
p
ns
indic
signific
radwan
obtain
vehicl
gaatreat
mice
subject
western
blot
analysi
protein
use
load
control
c
pool
spleen
cell
pool
group
also
wash
treat
pma
plu
ionomycin
stain
fitclabel
monoclon
antibodi
describ
method
wash
twice
cell
permeabil
bd
buffer
stain
dark
cell
